<DOC>
	<DOC>NCT03043794</DOC>
	<brief_summary>This is a Phase II trial of preoperative stereotactic radiation to the breast for low risk breast cancer.</brief_summary>
	<brief_title>Study of Stereotactic Radiotherapy for Breast Cancer</brief_title>
	<detailed_description>This is a single arm phase II study design, evaluating the pathologic response (primary endpoint) as well as toxicity, cosmetic outcome, quality of life, and translational correlates (secondary endpoints) to pre-operative stereotactic body radiotherapy (SBRT) to intact breast tumors in patients with hormone-receptor positive early stage breast cancer.</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Female sex Age &gt; or = to 50 years of age Invasive ductal carcinoma Clinically and radiographically T1 tumor Clinically node negative Clearly demarcated tumor on magnetic resonance imaging (MRI), as determined by treating physician (MRI may be done after enrollment if not done prior) Planning breast conserving surgery including sentinel node biopsy â‰¥10% expression of ER and/or PR HER2 using the current College of American Pathologists guidelines Postmenopausal Willing and able to provide informed consent Medical conditions that may increase risk for poor cosmetic outcome (i.e. Lupus, rheumatoid arthritis, scleroderma Pure DCIS without invasive cancer Patients who have received or will be receiving neoadjuvant systemic therapy, endocrine therapy, or targeted agents Breast implant in the involved breast unless the implant will be removed prior to initiation of study treatment Positive pregnancy test Subjects without placement of a biopsy clip at the diagnostic procedure who are unwilling to undergo clip placement. Unable to meet dosimetric constraints due to tumor location and/or patient anatomy Planning mastectomy Unable to tolerate prone positioning</criteria>
	<gender>Female</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>early stage</keyword>
	<keyword>low risk</keyword>
</DOC>